Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Research Coverage on Small and Micro-Cap Companies

Equity Bottom-Up

Arrowhead Pharmaceuticals  / Equity Bottom-Up

<ul><li>On September 2, 2024, Arrowhead Pharmaceuticals, Inc. (ARWR) announced results from the Phase 3 PALISADE study of plozasiran in patients with familial chylomicronemia syndrome (FCS).</li><li>The trial met its primary endpoint and all key secondary endpoints, including statistically significant reductions in triglycerides (TGs), apolipoprotein C-III (APOC3), and the incidence of acute pancreatitis.</li><li>The data were presented in a late-breaking oral presentation at the European Society of Cardiolog (ESG) Congress 2024 and simultaneously published in The New England Journal of Medicine.</li></ul>

On September 2, 2024, Arrowhead Pharmaceuticals, Inc. (ARWR) announced results from the Phase 3 PALISADE study of plozasiran in patients with familial chylomicronemia syndrome (FCS).The trial met its primary endpoint and all key secondary endpoints, including statistically significant reductions in triglycerides (TGs), apolipoprotein C-III (APOC3), and the incidence of acute pancreatitis.The data were presented in a late-breaking oral presentation at the European Society of Cardiolog (ESG) Congress 2024 and simultaneously published in The New England Journal of Medicine.

ARWR: PALISADE Phase 3 Results Published in NEJM 